Atlas Trials

Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

Clinical trial NCT03987867 · UNKNOWN

Trial details

NCT number
NCT03987867
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Non-small Cell Lung CancerFirst-line Treatment
Start date
2019-06-01
Primary completion
2021-06-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.